The Latest Breaking News from Pfizer

Children as young as six months will be able to get shots from either Pfizer or Moderna after Friday’s FDA approval

U.S. health advisers have recommended COVID-19 vaccines for infants, toddlers and preschoolers — the last group without the shots

Is there anyone’s life Ron DeSantis won’t endanger in his anticipated run for the White House?

U.S. kids under 5 — roughly 18 million youngsters — are eligible for the shots.

The vaccinations for children as young as 6 months old could start next week. But first, the Centers for Disease Control and Prevention must sign off.

The stock market gained but the Dow Jones inched lower on the eve of three-day weekend. Oil stocks tumble.

The U.S. Food and Drug Administration authorized COVID-19 vaccines for children under 5 years old Friday, a welcome relief to parents of the last age group to become eligible for shots. Although the move will help protect children from infection and serious disease, vaccine hesitancy still looms in the U.S.…

President Joe Biden says jabs could be rolled out to that age group as early as next week, pending CDC recommendations.

Moderna and Pfizer vaccine trials for children six months to five years old look promising and experts say the TGA is likely to approve both

For many parents of kids under age 5, a safe and effective COVID-19 vaccine could not come soon enough. A full year and a half after shots first became available for adults, their wait is nearly over.

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…